Can Total Diffusion Volume Predict Survival in mCRPC?
Metastatic castration-resistant prostate cancer presents significant management challenges for clinicians worldwide. Therefore, identifying accurate imaging biomarkers remains vital for patient risk stratification. Recent findings demonstrate that total diffusion volume derived from whole-body diffusion-weighted imaging strongly predicts overall survival. Consequently, this imaging metric offers clinicians a powerful tool to quantify total metastatic burden.
Role of Total Diffusion Volume in Risk Stratification
Historically, oncologists have relied on conventional bone scintigraphy and computerized tomography to assess skeletal lesions. However, these conventional imaging modalities often struggle to quantify functional tumor burden accurately. In contrast, whole-body diffusion-weighted MRI measures the microscopic mobility of water molecules in cellular tissue. Furthermore, artificial intelligence tools now assist radiologists in segmenting bone metastases on diffusion scans. As a result, calculating total diffusion volume has become both feasible and reproducible in clinical workflows.
Clinical Findings and Overall Survival Outcomes
Specifically, a large retrospective study evaluated 360 patients with metastatic castration-resistant disease. Notably, patients with higher total diffusion volume experienced significantly shorter median overall survival. In addition, multivariable regression models confirmed that this volumetric metric remains an independent prognostic factor. Conversely, global apparent diffusion coefficient did not retain statistical significance in full multivariable analysis. Thus, the physical volume of active diffusion restriction appears more prognostic than mean cellular diffusivity.
Implications for Clinical Decision-Making
Moreover, integrating this quantitative metric into standard staging protocols could optimize treatment sequencing. For example, high-risk patients may benefit from earlier treatment escalation or novel combination therapies. Therefore, adopting whole-body MRI in tertiary cancer centers in India could improve survival predictions. Ultimately, volumetric diffusion assessment provides actionable prognostic insight for advanced prostate cancer care.
Frequently Asked Questions
Q1: What is total diffusion volume in prostate cancer imaging?
Total diffusion volume represents the segmented sum of all active metastatic lesions measured on whole-body diffusion-weighted MRI scans.
Q2: How does total diffusion volume assist clinical oncologists?
Consequently, it provides an objective, quantitative biomarker of skeletal tumor burden that independently predicts overall patient survival.
References
- D’Erme L et al. Total diffusion volume on whole-body diffusion-weighted imaging is a strong prognostic marker of disease survival in metastatic castration-resistant prostate cancer. Eur Radiol. 2026 Aug 13. doi: 10.1007/s00330-026-12792-1. PMID: 42593500.
- Pérez-López R et al. Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer. Radiology. 2016;280(1):151-160.
- Padhani OI et al. Multiparametric Whole-Body MRI: A Game Changer in Metastatic Prostate Cancer. Cancers. 2024;16(14):2540.
